ArticlePsychopharmacology2026
Heightened excitability and impaired Inhibition in methamphetamine users: a pilot study of neurophysiological correlates of psychological symptoms.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, we investigated transcranial magnetic stimulation (TMS)-derived markers of excitability and inhibition in methamphetamine (METH) use disorder.
methodsSixteen methamphetamine users and 20 matched controls underwent psychological assessments, revised form of Symptom Checklist-90-Revised, cognitive assessment, anxiety and depression scales and TMS measures, including resting and active motor thresholds (RMT and AMT), motor evoked potential amplitude (MEP-A), cortical silent period (CSP), and short-interval intracortical inhibition (SICI).
resultsMETH users reported higher anxiety, depression, and somatization (p < 0.001), while cognition remained preserved. They exhibited reduced RMT and AMT (p < 0.001), indicating increased excitability, with no significant differences in MEP-A (p = 0.083). CSP onset latency was prolonged at 150% RMT (p = 0.042), suggesting impaired inhibition. Excitability thresholds correlated negatively with methamphetamine dose, while addiction duration was linked to CSP changes and obsessive-compulsive symptoms. Lower thresholds also correlated with greater interpersonal sensitivity and addiction severity.
conclusionIncreased cortical excitability and decreased inhibitory control are linked to METH usage, and these factors may be underlying psychiatric symptoms. TMS-derived indices show potential as biomarkers for neurophysiological monitoring and targeted interventions in methamphetamine use disorder.
Indexed as
Identifiers
41553513What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.